| Ms Sandra Jean Marx, MSW, LCSW | |
|
1492 S 800 W, Suite J, Woods Cross, UT 84087-2080 | |
| (801) 294-5224 | |
| (801) 294-5269 |
| Full Name | Ms Sandra Jean Marx |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1492 S 800 W, Woods Cross, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073810362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 111252-3501 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Sandra Jean Marx, MSW, LCSW 1492 S 800 W, Suite J, Woods Cross, UT 84087-2080 Ph: (801) 294-5224 | Ms Sandra Jean Marx, MSW, LCSW 1492 S 800 W, Suite J, Woods Cross, UT 84087-2080 Ph: (801) 294-5224 |
News Archive
After a three-day consultation on Zika research and development, international experts, convened by WHO, have agreed on top priorities to advance R&D for Zika medical products.
President Obama on Tuesday embarked on the difficult task of persuading Americans to reconsider his landmark health-care law after its botched launch, imploring people to sign up as part of a major push to publicize the benefits of the Affordable Care Act. Republicans immediately lampooned the effort -; coming more than three years after passage of the law and two months after its disastrous rollout -; and conservative activists vowed to wage a counterassault publicizing the law's downsides (Goldfarb and Eilperin, 12/3).
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.
› Verified 9 days ago
Rebecca W Kohler, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1576 S 500 W Ste 202, Woods Cross, UT 84010 Phone: 801-406-9002 | |
Mark Dale, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 576 W 900 S, Woods Cross, UT 84010 Phone: 801-397-4166 | |
Mrs. Jessica Lacey Fisher Champlin, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1290 S 500 W Ste 300, Woods Cross, UT 84010 Phone: 801-215-9575 Fax: 833-904-1668 | |
Mrs. Mikelle Mitzi Wrobel, SSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 763 W 700 S, Woods Cross, UT 84087 Phone: 801-292-2318 Fax: 801-295-2556 | |
Mr. Christopher Mark Tippets, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 592 W 1350 S, Woods Cross, UT 84010 Phone: 801-299-5317 |